Last reviewed · How we verify
Bupropion SR and XL
Bupropion SR and XL, marketed by North Dakota State University, is a well-established treatment in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its long-standing market presence and established patient base. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Bupropion SR and XL |
|---|---|
| Sponsor | North Dakota State University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors (PHASE3)
- Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial (PHASE4)
- Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use (NA)
- Lamotrigine and Bupropion for Meniere's Disease (PHASE2)
- A 7-year Assessment on Subject Understanding of ZYBAN/ WELLBUTRIN Associated Risks
- Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns (PHASE4)
- A Comparison of Sustained and Extended Release Bupropion Following Bariatric Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupropion SR and XL CI brief — competitive landscape report
- Bupropion SR and XL updates RSS · CI watch RSS
- North Dakota State University portfolio CI